Mr. Philip Theodore reports

AETERNA ZENTARIS ANNOUNCES IND SUBMISSION BY SINOPHARM A-THINK

Aeterna Zentaris Inc.'s licensee, Sinopharm A-Think Pharmaceuticals Co. Ltd., which is affiliated with the largest state-owned pharmaceutical company in the People's Republic of China, has submitted an investigational new drug application (IND) for Zoptrex to the Chinese State Food and Drug Administration (CFDA), remaining on track to commence its clinical program during the first half of 2017.

The IND submission follows Sinopharm A-Think's recent implementation of the processes for manufacturing Zoptrex, which will enable it to commence its clinical program with product manufactured locally. Dr. Richard Sachse, senior vice-president, and chief medical and scientific officer of the company, stated: "The company's Frankfurt-based personnel assisted Sinopharm A-Think with the IND by providing extensive information regarding the chemistry, manufacturing and controls related to the manufacture of Zoptrex. We are pleased that we were able to assist our licensee to achieve this important step in their clinical development of Zoptrex. I remain very impressed by the progress that Sinopharm A-Think is making."

We seek Safe Harbor.